Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Sunitinib malate
As low as
CHF 271.00
In stock
Only %1 left
CDX-S0330-G0011 gCHF 271.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | Sunitinib L-malate; SU112248; N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt |
| Product Type | Chemical |
| Properties | |
| Formula | C22H27FN4O2 . C4H6O5 |
| MW | 532.56 |
| CAS | 341031-54-7 |
| RTECS | UX9356900 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Yellow, orange to brown powder. |
| Solubility | Soluble in DMSO (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | LBWFXVZLPYTWQI-IPOVEDGCSA-N |
| Smiles | CC1=C(/C=C2C(NC3=C\2C=C(F)C=C3)=O)NC(C)=C1C(NCCN(CC)CC)=O.O[C@H](C(O)=O)CC(O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at RT. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
Sunitinib malate is a potent ATP-competitive and cell permeable multi-targeted receptor tyrosine kinase (RTK) inhibitor targeting VEGFR, PDGFR-β and c-Kit (Ki = 2-17nM). It inhibits FLK1 (Ki=9nM), PDGFRβ (Ki=8nM) and FLT3. It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl and Src. Sunitinib malate inhibits the cellular receptor phosphorylation of FLT3, RET and CSF-1R. Sunitinib malate exhibits potent antiangiogenic and antitumor activity in multiple xenograft models. It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.
Product-specific References
(1) L. Sun, et al.; J. Med. Chem. 46, 1116 (2003) | (2) D. B. Mendel, et al.; Clin. Cancer Res. 9, 327 (2003) | (3) A.M. O'Farrell, et al.; Blood 101, 3597 (2003) | (4) J. Guo, et al.; Mol. Cancer. Ther. 5, 1007 (2006) | (5) E.D. Deeks & G.M. Keating; Drugs 66, 2255 (2006) | (6) S. Faivre, et al.; Nat. Rev. Drug Discov. 6, 734 (2007) | (7) R. Roskoski; BBRC 356, 323 (2007)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF